These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10761211)

  • 1. [Combined tumor chemotherapy/gene therapy based on the activation of antineoplastic agents by genetic constructions of cytochromes p450].
    Sokolova NN; Iatsenko AN; Pokrovskaia MV
    Vopr Med Khim; 1999; 45(6):462-71. PubMed ID: 10761211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
    Mohr L; Rainov NG; Mohr UG; Wands JR
    Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
    Huang Z; Waxman DJ
    Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Res; 2002 Dec; 62(23):6928-37. PubMed ID: 12460909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
    Günzburg WH; Salmons B
    Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene therapy of malignant tumors].
    Schackert HK; Frost P
    Chirurg; 1993 Sep; 64(9):678-83. PubMed ID: 8222924
    [No Abstract]   [Full Text] [Related]  

  • 13. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
    Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
    Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
    Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
    Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy.
    Steffens S; Frank S; Fischer U; Heuser C; Meyer KL; Dobberstein KU; Rainov NG; Kramm CM
    Cancer Gene Ther; 2000 May; 7(5):806-12. PubMed ID: 10830728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suicide gene therapy using E. coli beta-galactosidase.
    Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.
    Searle PF; Chen MJ; Hu L; Race PR; Lovering AL; Grove JI; Guise C; Jaberipour M; James ND; Mautner V; Young LS; Kerr DJ; Mountain A; White SA; Hyde EI
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):811-6. PubMed ID: 15566399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
    Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
    Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.